isoniazid has been researched along with Psoriasis in 24 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Isoniazid is an antibiotic with high bactericidal effect on replicating mycobacteria and constitutes the most commonly prescribed treatment for latent tuberculosis infection." | 7.91 | Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases. ( Giácaman-von der Weth, M; Hernández-Bel, P; Partarrieu-Mejías, F; Pérez-Ferriols, A, 2019) |
| " Objective The aim of this study was to present the follow-up results for Isoniazid (INH) chemoprophylaxis in patients with psoriasis receiving different biological therapies." | 7.83 | Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia. ( Cataño, J; Morales, M, 2016) |
| "Isoniazid therapy was started with marked improvement of psoriatic lesions before biologic treatment could be initiated." | 5.40 | Improvement in severe psoriasis associated with isoniazid treatment. ( Brzezinski, P; Chiriac, A; Feldman, SR; Ferariu, D; Solovan, C, 2014) |
| "To evaluate the safety of isoniazid (INH) prophylaxis for newly identified latent tuberculosis infection (LTBI) in ustekinumab-treated patients with psoriasis." | 5.16 | The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. ( Ho, V; Kato, T; Leonardi, C; Li, S; Shen, YK; Song, M; Szapary, P; Tsai, TF; Wasfi, Y, 2012) |
| " Isoniazid is an antibiotic with high bactericidal effect on replicating mycobacteria and constitutes the most commonly prescribed treatment for latent tuberculosis infection." | 3.91 | Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases. ( Giácaman-von der Weth, M; Hernández-Bel, P; Partarrieu-Mejías, F; Pérez-Ferriols, A, 2019) |
| " Objective The aim of this study was to present the follow-up results for Isoniazid (INH) chemoprophylaxis in patients with psoriasis receiving different biological therapies." | 3.83 | Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia. ( Cataño, J; Morales, M, 2016) |
| " Latent tuberculosis was diagnosed at baseline and the patient was treated with isoniazid for 9 months." | 3.76 | Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis. ( Ferguglia, G; Laria, G; Prestinari, F, 2010) |
| "Although rare, tuberculosis has been reported with biologic treatment against psoriasis in Japan, a tuberculosis medium-burden country." | 1.56 | Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities. ( Furue, M; Hayashi, H; Higashi, Y; Hino, R; Imafuku, S; Kaneko, S; Kikuchi, S; Koike, Y; Matsuzaka, Y; Mitoma, C; Miyagi, T; Morizane, S; Nakahara, T; Nakamura, M; Nomura, H; Ohata, C; Ohyama, B; Okazaki, F; Sawada, Y; Sugita, K; Takahashi, K; Tsuruta, N; Yamaguchi, K; Yamaguchi, M; Yanase, T; Yonekura, K, 2020) |
| "Psoriatic patients with latent tuberculosis infection (LTBI) need a prophylaxis before starting a treatment with biological drugs." | 1.46 | Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. ( Conti, A; Galdo, G; Gisondi, P; Lasagni, C; Odorici, G; Pellacani, G; Piaserico, S, 2017) |
| "The reactivation of a latent tuberculosis infection is one of the possible major events that may occur during biologic therapies for inflammatory chronic diseases such as psoriasis." | 1.42 | Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida. ( Dehesa, L; Kerdel, F; Medina-Gil, C; Vega, A, 2015) |
| "Isoniazid therapy was started with marked improvement of psoriatic lesions before biologic treatment could be initiated." | 1.40 | Improvement in severe psoriasis associated with isoniazid treatment. ( Brzezinski, P; Chiriac, A; Feldman, SR; Ferariu, D; Solovan, C, 2014) |
| "Screening for latent tuberculosis infection (LTBI) is mandatory in patients with psoriasis prior to biological therapy." | 1.40 | Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. ( Girolomoni, G; Gisondi, P; Lo Cascio, G; Pezzolo, E, 2014) |
| "A case of acute respiratory failure due to diaphragmatic weakness following adalimumab therapy for psoriasis is described." | 1.35 | Acute bilateral phrenic neuropathy following treatment with adalimumab. ( Alexopoulou, A; Antoniou, C; Archimandritis, A; Katsambas, A; Katsaounis, P; Kilidireas, K; Koskinas, J; Papageorgiou, C; Soultati, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Megna, M | 1 |
| Patruno, C | 1 |
| Bongiorno, MR | 1 |
| Gambardella, A | 1 |
| Guarneri, C | 1 |
| Foti, C | 1 |
| Lembo, S | 1 |
| Loconsole, F | 1 |
| Fabbrocini, G | 1 |
| Kaneko, S | 1 |
| Tsuruta, N | 1 |
| Yamaguchi, K | 1 |
| Miyagi, T | 1 |
| Takahashi, K | 1 |
| Higashi, Y | 1 |
| Morizane, S | 1 |
| Nomura, H | 1 |
| Yamaguchi, M | 1 |
| Hino, R | 1 |
| Sawada, Y | 1 |
| Nakamura, M | 1 |
| Ohyama, B | 1 |
| Ohata, C | 1 |
| Yonekura, K | 1 |
| Hayashi, H | 1 |
| Yanase, T | 1 |
| Matsuzaka, Y | 1 |
| Sugita, K | 1 |
| Kikuchi, S | 1 |
| Mitoma, C | 1 |
| Nakahara, T | 1 |
| Furue, M | 1 |
| Okazaki, F | 1 |
| Koike, Y | 1 |
| Imafuku, S | 1 |
| Machado, Á | 1 |
| Abreu, M | 1 |
| Torres, T | 1 |
| Baççıoğlu, A | 1 |
| Karabulut, AA | 1 |
| Kalpaklıoğlu, AF | 1 |
| Momose, M | 1 |
| Asahina, A | 1 |
| Hayashi, M | 1 |
| Yanaba, K | 1 |
| Umezawa, Y | 1 |
| Nakagawa, H | 1 |
| Conti, A | 1 |
| Piaserico, S | 1 |
| Gisondi, P | 2 |
| Odorici, G | 1 |
| Galdo, G | 1 |
| Lasagni, C | 1 |
| Pellacani, G | 1 |
| Huang, TH | 1 |
| Wei, YC | 1 |
| Lan, CE | 1 |
| Snast, I | 1 |
| Bercovici, E | 1 |
| Avni, T | 1 |
| Shitenberg, D | 1 |
| Hodak, E | 1 |
| Pavlovsky, L | 1 |
| Partarrieu-Mejías, F | 1 |
| Hernández-Bel, P | 1 |
| Giácaman-von der Weth, M | 1 |
| Pérez-Ferriols, A | 1 |
| Sánchez-Moya, AI | 2 |
| Dauden, E | 2 |
| Chiriac, A | 1 |
| Ferariu, D | 1 |
| Solovan, C | 1 |
| Brzezinski, P | 1 |
| Feldman, SR | 1 |
| Pezzolo, E | 1 |
| Lo Cascio, G | 1 |
| Girolomoni, G | 1 |
| Medina-Gil, C | 1 |
| Dehesa, L | 1 |
| Vega, A | 1 |
| Kerdel, F | 1 |
| Cataño, J | 1 |
| Morales, M | 1 |
| Alexopoulou, A | 1 |
| Koskinas, J | 1 |
| Soultati, A | 1 |
| Katsaounis, P | 1 |
| Kilidireas, K | 1 |
| Papageorgiou, C | 1 |
| Antoniou, C | 1 |
| Katsambas, A | 1 |
| Archimandritis, A | 1 |
| Prestinari, F | 1 |
| Ferguglia, G | 1 |
| Laria, G | 1 |
| Tsai, TF | 2 |
| Ho, V | 1 |
| Song, M | 2 |
| Szapary, P | 1 |
| Kato, T | 1 |
| Wasfi, Y | 1 |
| Li, S | 1 |
| Shen, YK | 1 |
| Leonardi, C | 1 |
| Chiu, HY | 1 |
| Chan, D | 1 |
| Shear, NH | 1 |
| Fernández López, E | 1 |
| de Unamuno Pérez, P | 1 |
| Kagramanova, AT | 1 |
| Tishchenko, LD | 1 |
| Rowe, E | 1 |
| Meffert, H | 1 |
| Wischnewsky, GG | 1 |
| Fellner, MJ | 1 |
1 review available for isoniazid and Psoriasis
| Article | Year |
|---|---|
[New approach to the pathogenetic therapy of psoriasis].
Topics: Adult; Drug Evaluation; Humans; Isoniazid; Methods; Middle Aged; Polyamines; Psoriasis; Tablets | 1987 |
2 trials available for isoniazid and Psoriasis
| Article | Year |
|---|---|
Isoniazid therapy for latent tuberculosis in psoriasis patients receiving biological agents: is it safe and efficacious?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Female; Humans; Immunosuppressive A | 2014 |
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Case-Contro | 2012 |
21 other studies available for isoniazid and Psoriasis
| Article | Year |
|---|---|
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.
Topics: Antibodies, Monoclonal, Humanized; Humans; Isoniazid; Latent Tuberculosis; Psoriasis; Retrospective | 2022 |
Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Biological Products; Child; Femal | 2020 |
Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Contraindications, Drug; Dermatologi | 2020 |
Erythema Multiforme-like Dermatitis Due to Isoniazid Hypersensitivity in a Patient With Psoriasis.
Topics: Dermatitis; Erythema Multiforme; Humans; Isoniazid; Psoriasis | 2021 |
Biologic treatments for elderly patients with psoriasis.
Topics: Adalimumab; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Biological Products; Cerebr | 2017 |
Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
Topics: Aged; Antitubercular Agents; Biological Products; Dermatologic Agents; Female; Follow-Up Studies; Hu | 2017 |
QuantiFERON®-TB Gold test conversion in a psoriatic patient with pleural tuberculosis one year after adalimumab treatment.
Topics: Adalimumab; Anti-Inflammatory Agents; Antitubercular Agents; Biopsy; Humans; Isoniazid; Male; Middle | 2018 |
Tuberculosis Screening in Patients with Psoriasis Receiving Biologic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Antitubercular Agents; Biological Products; Chemoprevention; Female; Humans; Isoniazid; | 2018 |
Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases.
Topics: Aged; Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Psor | 2019 |
Improvement in severe psoriasis associated with isoniazid treatment.
Topics: Aged; Antitubercular Agents; Facial Dermatoses; Humans; Isoniazid; Male; Psoriasis; Tuberculosis | 2014 |
Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Biolog | 2014 |
Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclon | 2015 |
Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia.
Topics: Adult; Aged; Antitubercular Agents; Colombia; Female; Humans; Immunosuppressive Agents; Isoniazid; L | 2016 |
Acute bilateral phrenic neuropathy following treatment with adalimumab.
Topics: Acute Disease; Adalimumab; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoc | 2009 |
Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis.
Topics: Antitubercular Agents; Etanercept; Hepatitis B; Humans; Immunoglobulin G; Immunologic Factors; Isoni | 2010 |
Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monocl | 2011 |
A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Dermatologic Agents; Humans; Isoniaz | 2013 |
'Is it safe?' Safety is a process, not a question.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Female; Humans; Is | 2012 |
[A case of excellent response to efalizumab. Experience in the University Hospital of Salamanca].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Biological Product | 2008 |
[Therapeutic trial with isonicotinic acid hydrazide in chronic stationary psoriasis].
Topics: Adult; Chronic Disease; Female; Humans; Isoniazid; Male; Middle Aged; Psoriasis | 1985 |
[Adverse effects of isoniazid].
Topics: Desensitization, Immunologic; Diagnosis, Differential; Drug Hypersensitivity; Drug Tolerance; Exanth | 1970 |